These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 23261172

  • 1. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
    Kwakernaak AJ, Lambert G, Slagman MC, Waanders F, Laverman GD, Petrides F, Dikkeschei BD, Navis G, Dullaart RP.
    Atherosclerosis; 2013 Feb; 226(2):459-65. PubMed ID: 23261172
    [Abstract] [Full Text] [Related]

  • 2. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P, Stenman UH, Gylling H.
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [Abstract] [Full Text] [Related]

  • 3. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A, Kappelle PJ, Lambert G, Dullaart RP.
    Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
    [Abstract] [Full Text] [Related]

  • 4. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M, Plana N, Ibarretxe D, Cabré A, González M, Ribalta J, Masana L.
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [Abstract] [Full Text] [Related]

  • 5. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S, Xu RX, Guo YL, Zhang Y, Zhu CG, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [Abstract] [Full Text] [Related]

  • 6. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K, Park BS, Kim YW, Vaziri ND.
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [Abstract] [Full Text] [Related]

  • 7. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC, Konrad RJ, van Himbergen TM, Isaacs A, Otokozawa S, Troutt JS, Schaefer EJ, van Greevenbroek MM, Stalenhoef AF, de Graaf J.
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
    [Abstract] [Full Text] [Related]

  • 8. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N.
    J Diabetes Complications; 2015 Nov; 29(8):1165-70. PubMed ID: 26412029
    [Abstract] [Full Text] [Related]

  • 9. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS.
    Circulation; 2013 Aug 27; 128(9):962-9. PubMed ID: 23884353
    [Abstract] [Full Text] [Related]

  • 10. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
    Kwakernaak AJ, Lambert G, Dullaart RP.
    Clin Biochem; 2012 Nov 27; 45(16-17):1522-4. PubMed ID: 22809551
    [Abstract] [Full Text] [Related]

  • 11. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins.
    Kwakernaak AJ, Lambert G, Dullaart RP.
    Clin Biochem; 2014 May 27; 47(7-8):679-82. PubMed ID: 24680982
    [Abstract] [Full Text] [Related]

  • 12. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.
    Transl Res; 2012 Aug 27; 160(2):125-30. PubMed ID: 22683370
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.
    Kwakernaak AJ, Lambert G, Muller Kobold AC, Dullaart RP.
    Thyroid; 2013 Feb 27; 23(2):166-72. PubMed ID: 23106476
    [Abstract] [Full Text] [Related]

  • 15. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
    Li S, Xu RX, Zhang Y, Guo YL, Zhu CG, Liu G, Dong Q, Li JJ.
    J Endocrinol Invest; 2015 Dec 27; 38(12):1291-9. PubMed ID: 26003826
    [Abstract] [Full Text] [Related]

  • 16. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients.
    Chan DC, Hamilton SJ, Rye KA, Chew GT, Jenkins AJ, Lambert G, Watts GF.
    Diabetes Obes Metab; 2010 Sep 27; 12(9):752-6. PubMed ID: 20649626
    [Abstract] [Full Text] [Related]

  • 17. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
    Chan DC, Wong AT, Pang J, Barrett PH, Watts GF.
    Clin Sci (Lond); 2015 Mar 27; 128(6):379-85. PubMed ID: 25291660
    [Abstract] [Full Text] [Related]

  • 18. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M.
    J Clin Endocrinol Metab; 2015 Jan 27; 100(1):E41-9. PubMed ID: 25313916
    [Abstract] [Full Text] [Related]

  • 19. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
    Wassef H, Bissonnette S, Saint-Pierre N, Lamantia V, Cyr Y, Chrétien M, Faraj M.
    J Clin Lipidol; 2015 Jan 27; 9(5):664-75. PubMed ID: 26350813
    [Abstract] [Full Text] [Related]

  • 20. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M, Terao Y, Ayaori M, Uto-Kondo H, Iizuka M, Yogo M, Hagisawa K, Takiguchi S, Yakushiji E, Nakaya K, Ogura M, Komatsu T, Ikewaki K.
    Arterioscler Thromb Vasc Biol; 2014 Jun 27; 34(6):1171-8. PubMed ID: 24675665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.